New Guideline Gives Active Surveillance a Boost : vimarsana.

The 2022 guidance for the first time makes active surveillance the recommended treatment for select patients with favorable intermediate-risk Gleason 3+4 prostate cancer.

Related Keywords

New York , United States , Memorial Sloan Kettering Cancer Center , Ann Arbor , Michigan , American , Rick Davis , Jamesa Eastham , Todd Morgan , Petert Scardino , James Schraidt , Morgan , Ancan Foundation , American Society For Radiation Oncology , Research Professor , American Urological Association , National Comprehensive Cancer Network , American Society , Radiation Oncology , New York City , Medscape Medical , Jack Lapides , Michigan Medicine , Active Surveillance , Localized Prostate Cancer , Prostate Carcinoma , Alignant Prostate Neoplasm , Prostate Cancer , Ancer Prostate , Clinical Guidelines , Guidelines , Activism , Activist , Social Issues , Biopsy , Chemotherapy , Neoadjuvant , Clinical Research , Clinical Trials , Linical Studies , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology , Cancer Risk , Cancer , Alignant Neopla ,